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 Summary
 Background: To assess the role of diffusion-weighted MR imaging in differentiation between Graves’ disease and 
painless thyroiditis.
 Material/Methods: A prospective study was conducted among 37 consecutive patients with untreated thyrotoxicosis 
(25 female and 12 male; mean age of 44 years) and 15 age- and sex-matched controls. Diffusion-
weighted MR imaging of the thyroid gland was performed in patients and controls. The apparent 
diffusion coefficient (ADC) value of the thyroid gland was calculated and correlated with Tc-99m 
uptake and thyroid function tests of the patients.
 Results: There was a significant difference in the ADC value of the thyroid gland between patients and 
the control group (P=0.001). The mean ADC value of the thyroid gland in Graves’ disease was 
2.03±0.28×10–3 mm2/sec, and in patients with painless thyroiditis 1.46±0.22×10–3 mm2/sec, 
respectively. There was a significant difference in the ADC values between Graves’ disease and 
painless thyroiditis (P=0.001). When the ADC value of 1.45×10–3 mm2/sec was used as a threshold 
value for differentiating Graves’ disease from painless thyroiditis, the best result was obtained with 
area under the curve of 0.934, accuracy of 83.8%, sensitivity of 95.8%, and specificity of 61.5%. 
The mean ADC value of the thyroid gland in patients positively correlated with serum TRAb and 
Tc-99m uptake (r=0.57, P=0.001 and r=0.74, P=0.001, respectively).
 Conclusions: We concluded that ADC values of the thyroid gland can be used to differentiate Graves’ disease 
from painless thyroiditis in patients with untreated thyrotoxicosis.
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Thyrotoxicosis results from thyroid hormone overproduc-
tion in Graves’ disease, or from thyroid hormone leak-
age from damaged or inflamed thyroid tissue in painless 
thyroiditis. Differentiation between these two entities 
is important for selection of proper therapy. Graves’ dis-
ease is treated with anti-thyroid drugs, radioactive iodine, 
and thyroidectomy, whereas destruction-induced thyro-
toxicosis in painless thyroiditis is a self-limiting disorder 
that can be managed conservatively. If painless thyroiditis 
is misdiagnosed as Graves’ disease and treated with anti-
thyroid drugs, hypothyroidism, drug-induced hepatitis, 
and leucopenia may occur [1–5]. Graves’ disease is an auto-
immune disorder characterized by the formation of auto-
antibodies that are directed against the thyroid stimulat-
ing hormone receptors. These antibodies lead to thyroid 
follicular hyperplasia with a subsequent excessive thyroid 
hormone production and suppression of thyroid stimulat-
ing hormone. Painless thyroiditis, also known as silent thy-
roiditis or subacute lymphocytic thyroiditis, is caused by 
lymphocytic infiltration of the thyroid follicles, secondary 
Authors’ Contribution:
 A Study Design
 B Data Collection
 C Statistical Analysis
 D Data Interpretation
 E Manuscript Preparation
 F Literature Search
 G Funds Collection
Signature: © Pol J Radiol, 2017; 82: 536-541
DOI: 10.12659/PJR.902416
O R I G I N A L  A R T I C L E
536
to an autoimmune response. This lymphocytic infiltration 
leads to thyroid follicular disruption with a release of an 
excess of thyroid hormones and subsequent transient thy-
rotoxicosis [1–3]. The presence of serum anti-thyrotropin 
receptor antibodies (TRAb) is regarded as a useful marker 
that can discriminate between Graves’ disease and pain-
less thyroiditis. However, it is not widely available with 
overlap in its values [6–9]. Different imaging modalities 
are used for assessing patients with thyrotoxicosis [5]. 
Color Doppler ultrasonography was used to investigate the 
pathogenesis of thyrotoxicosis. However, this examination 
is not satisfactory in all patients, and the results are oper-
ator-dependent [10–14]. Scintigraphy of the thyroid gland is 
the gold standard for evaluation of thyrotoxicosis, but it is 
associated with radiation exposure, long examination time, 
and is contraindicated during lactation [15–17].
Diffusion-weighted MR imaging is a noninvasive imag-
ing tool with no exposure to ionizing radiation. Diffusion-
weighted imaging provides information on the random 
motion of water molecules in tissues, which indicates tis-
sue cellularity [18–20]. Diffusion-weighted MR imaging 
was used for characterization of thyroid nodules [21–23], 
evaluation of diffuse thyroid diseases [24], assessment of 
Graves’ disease activity, and prediction of therapeutic out-
comes [25]. Two recent studies discussed the role of dif-
fusion-weighted MR imaging in differentiating between 
Graves’ disease, Hashimoto’s thyroiditis, and painless thy-
roiditis [26,27].
The aim of this work was to assess the role of diffusion-
weighted MR imaging in the differentiation between 
Graves’ disease and painless thyroiditis.
Material and Methods
Patients
Approval of the institutional review board for this study 
was obtained, and informed consents were obtained from 
patients and volunteers. This prospective study was con-
ducted in 42 consecutive patients with untreated thyrotoxi-
cosis. Their age ranged from 22 to 52 years, the mean age 
was 44 years. Five patients were excluded from the study 
due to presence of multiple thyroid nodules (3 patients) and 
claustrophobia (2 patients). A control group consisting of 
15 volunteers was randomly selected from patients who 
were referred for cervical MR imaging examinations. The 
mean age and male-to-female ratio of the two groups were 
matched. All patients and controls underwent diffusion-
weighted MR imaging of the thyroid gland and laboratory 
testing; only the patients underwent thyroid scintigraphy. 
Graves’ disease was diagnosed on the basis of clinical find-
ings and laboratory tests that showed high values of free 
thyroxine (FT4) and free tri-iodothyronine (FT3), low levels 
of thyrotropin-stimulating hormone (TSH), and increased 
TSH receptor antibody (TRAb) titer. Painless thyroiditis was 
diagnosed based on increased levels of FT4 and FT3 for less 
than 3 months, and/or later development of transient hypo-
thyroidism, without neck pain or tenderness. This study 
involved 24 patients with Graves’ disease (female/male; 
17/7, mean age 43.3 years) and 13 patients with painless 
thyroiditis (female/male; 8/5, mean age 41.2 years).
MR imaging
MR images were obtained with a superconducting 1.5 T 
MR imaging unit (Achieva, Philips Healthcare, Best, The 
Netherlands). We used a dedicated eight-channel neck coil 
(Achieva Sense; Philips Healthcare, Best, Netherlands). 
Patients were placed in a supine position, with the 
CP-neck array coil placed in such a way that the thy-
roid gland was located in the central portion of the field 
of view. Axial, fast filed echo (FFE) images were acquired 
using the following parameters: TR/TE=800/20 msec, 
flip angle=20 degrees, section thickness=4 mm, inter-
section gap=1 mm, matrix=192×256, and field of view 
(FOV)=20–23 cm. Diffusion-weighted MR imaging of 
the thyroid gland was performed in axial plane using 
the spin-echo type of echo-planar sequence. The imag-
ing parameters were TR/TE=4200/140 msec, NEX=6, 
bandwidth=1345 Hz/pixel, field of view=20–23 cm, 
matrix=256×128, slice thickness=4 mm, intersection 
gap=1 mm and b-values=0, 400 and 800 sec/mm2. The dif-
fusion gradients were applied in three orthogonal direc-
tions (X, Y, and Z). The scanning time of diffusion-weighted 
MR imaging was 135 seconds. The ADC maps were auto-
matically generated on the operating console with commer-
cially available software.
Image analysis
Image analysis was performed in consensus by two radi-
ologists (AA and SS), experts in head and neck imaging (20 
and 10 years of experience). A region of interest was drawn 
around both thyroid lobes and isthmus in 3 different sec-
tions of the ADC map (Figure 1). The sections that were 
selected for analysis showed homogeneous thyroid paren-
chyma that was not affected by artifacts due to chemi-
cal shift, magnetic susceptibility, or vascular motion. The 
ADC value was automatically calculated and expressed in 
10–3 mm2/sec. The final ADC per-subject value that was 
used for statistical analysis was the average of these three 
ADC values. In the control group, the sections that showed 
homogeneous thyroid parenchyma were similarly selected 
for analysis.
Thyroid scintigraphy
After an intravenous injection of 185 MBq Tc-99m pertech-
netate (5 mCi), thyroid scans were performed using a 
gamma camera with low-energy, high-sensitivity, parallel-
hole collimator. The collimator was centered over the thy-
roid at a distance of 10 cm. Imaging commenced approxi-
mately 20 minutes after injection. The images were record-
ed for 180 s, with a matrix size of 512×512 and a 2-fold 
magnification. A region of interest was drawn around the 
borders of the thyroid gland, and another region of interest 
in the supraclavicular area was used for background sub-
traction to calculate the thyroid uptake [16].
Laboratory tests
Serum concentrations of TSH, FT4, and FT3 were meas-
ured with an electrochemiluminescence immunoassay 
(ECLUSYS TSH, FT 4 and FT 3; Roche Diagnostics KK, 
Tokyo, Japan). Serum TRAb levels were measured by a 
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radioreceptor assay (DYNO test TRAb human; Yamasa Co., 
Chiba, Japan). The normal range for TRAb was set below 
1.0 IU/l. The time delay between the diffusion MR imag-
ing of the thyroid gland and thyroid function tests ranged 
between 4–6 days.
Statistical analysis
The statistical analysis of data was performed with 
Statistical Package for Social Science software, version 
21 (SPSS Inc., Chicago, Ill, USA). Qualitative data were 
described with counts and percentages. Associations 
between categorical variables was tested with the chi-
squared test. For parametric data, continuous variables 
were presented as means and standard deviations (mean 
±SD). The Kolmogorov-Smirnov test was used to test the 
normality of quantitative data. The ADC values were nor-
mally distributed, whereas the Tc-99m uptake levels and 
TRAb, TSH, FT3, and FT4 levels were non-normal. For 
parametric data, Student’s t tests and one-way analysis of 
variance (ANOVA) were used. Mann-Whitney U tests and 
Kruskal-Wallis tests were used to compare non-parametric 
variables. ROC (Receiver Operating Characteristic) curves 
were drawn to detect optimal cut-off ADC values for dif-
ferentiation between patients with thyrotoxicosis and 
controls. This ADC value, Tc-99m uptake levels, and TRAb 
levels discriminated between Graves’ disease and painless 
thyroiditis with the best accuracy. P value of £0.05 was 
considered to be statistically significant. The Spearman’s 
coefficient was used to evaluate the degree of correlation 
between the ADC value of the thyroid gland, Tc-99m uptake 
levels, and laboratory tests (TRAb, TSH, FT4, and FT3).
Results
This study included the three following groups: a group 
of patients with Graves’ disease (n=24) (Figure 1), a group 
of patients with painless thyroiditis (n=13), and a control 
Figure 1.  Graves’ disease: (A) Axial, fast filed echo image shows diffusely enlarged both thyroid lobes and isthmus. (B) ADC map shows high ADC 
values of the thyroid gland (1.9×10–3 mm2/sec). (C) ADC map with localization of the region of interest.
A B C
Mean ±SD Minimum Maximum
Graves’ disease (n=24) 2.03±0.28 1.45 2.5
Painless thyroiditis (n=13) 1.46±0.22 1.22 1.91
Thyrotoxicosis (n=37) 1.83±0.38 1.22 2.5
Control group (n=15) 1.02±0.14 0.85 1.3
Table 1.  The mean, standard deviation, minimum, and maximum ADC values (×10–3 mm2/sec) of the thyroid gland in Graves’ disease, painless 
thyroiditis, thyrotoxicosis, and in control group.













































Table 2.  The median, minimum, and maximum of Tc-99m uptake values and the thyroid function tests in patients with Graves’ disease, painless 
thyroiditis, thyrotoxicosis, and control group.
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group (n=15). Table 1 shows the ADC values, and Table 2 
shows the Tc-99m uptake levels and laboratory tests 
(TRAb, TSH, FT3, and FT4) of patients and controls.
The mean ADC value of the thyroid gland in patients with 
thyrotoxicosis was 1.83±0.38×10–3 mm2/sec, and in the 
control group it was 1.02±0.14×10–3 mm2/sec. There was 
a significant difference in the ADC value between patients 
with thyrotoxicosis and controls (P=0.001). The cut-off 
ADC value that was used for differentiating patients from 
controls was ³1.3×10–3 mm2/sec, with area under the curve 
of 0.99, accuracy of 94.2%, sensitivity of 91.9%, specificity 
of 100%, positive predictive value of 100%, and negative 
predictive value of 83.3% (Figure 2). There was a significant 
difference in serum TSH, FT3, and FT4 levels between both 
patient groups and the control group (P=0.001).
The mean ADC value in patients with Graves’ disease was 
2.03±0.28×10–3 mm2/sec, and in patients with painless 
thyroiditis it was 1.46±0.22×10–3 mm2/sec. There was a 
significant difference in the ADC value between patients 
with Graves’ disease and painless thyroiditis (P=0.001). 
The cut-off ADC value of the thyroid gland that was used 
for differentiating Graves’ disease from painless thyroidi-
tis was ³1.45×10–3 mm2/sec, with area under the curve of 
0.934, accuracy of 83.8%, sensitivity of 95.8%, specificity 
of 61.5%, positive predictive value of 82.1%, and negative 
predictive value of 88.9% (Figure 3).
The median Tc-99m uptake values in patients with Graves’ 
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Figure 2.  Receiver operating characteristic (ROC) curve. The cut-off 
ADC value that was used for differentiating thyrotoxicosis 
from normal thyroid parenchyma was ³1.3×10–3 mm2/sec, 
with sensitivity of 91.9%, specificity of 100%, accuracy of 













Figure 4.  Scatter plot showing a positive correlation between ADC 
and Tc-99m uptake values. There is a positive correlation 














Figure 5.  Scatter plot showing correlation between ADC values and 
TRAb levels. There is a positive correlation between the ADC 
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Figure 3.  Receiver operating characteristic (ROC) curve. The cut-off 
ADC value that was used for differentiating patients with 
Graves’ disease from patients with painless thyroiditis was 
³1.45×10–3 mm2/sec, with sensitivity of 95.8%, specificity of 
61.5%, accuracy of 83.8%, and area under the curve of 0.934.
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those found in patients with painless thyroiditis (0.46%). 
The cut-off value of Tc-99m uptake that was used to dis-
criminate Graves’ disease from painless thyroiditis was 
³1.23, with area under the curve of 0.997, accuracy of 
97.3%, sensitivity of 100%, specificity of 92.3%, positive 
predictive value of 96%, and negative predictive value 
of 100%. There was a positive correlation between the 
ADC values and Tc-99m uptake values (r=0.74, P=0.001) 
(Figure 4).
The median serum level of TRAb in patients with Graves’ 
disease (3.44 IU/ml) was significantly higher (P=0.001) 
than in patients with painless thyroiditis (0.93 IU/ml). 
The serum level of TRAb in patients with thyrotoxicosis 
showed a positive correlation with ADC values (r=0.57, 
P=0.001) (Figure 5). The ADC values of the thyroid gland in 
patients with thyrotoxicosis revealed a positive correlation 
with serum TSH (r=0.22, P=0.39), and a negative correla-
tion with serum FT3 (r=–0.28, P=0.22) and FT4 (r=–0.29, 
P=0.29).
Discussion
The main findings of this study are that the ADC value of 
the thyroid gland, Tc-99m thyroid uptake, and serum TRAb 
levels are significantly different in patients with Graves’ 
disease in comparison to patients with painless thyroiditis. 
The ADC value of the thyroid gland is well correlated with 
Tc-99m thyroid uptake and serum TRAb levels.
In the current study, there was a significant difference 
(P=0.001) in the ADC value of the thyroid gland parenchy-
ma in patients with thyrotoxicosis and controls. A previ-
ous study reported that the mean ADC values of the thy-
roid gland in healthy volunteers were 2.93×10–3 mm2/sec, 
1.97×10–3 mm2/sec, and 1.62×10–3 mm2/sec at b=100, 
b=600, and b=1000 sec/mm2, respectively. Also, the opti-
mal threshold values of ADC and TRAb that was used to 
differentiate patients from controls were 1.837×10–3 
mm2/sec and 1.350 IU/ml, respectively [26].
One study reported that the optimal threshold ADC value 
that was used to differentiate Graves’ disease from pain-
less thyroiditis was 1.837×10–3 mm2/sec, with sensitiv-
ity, specificity, accuracy, PPV, and NPV of 96.078, 91.892, 
95.000, 97.059 and 89.474%, respectively [27]. Another 
study added that the ADC value was significantly higher 
in patients with Graves’ disease in comparison to patients 
with painless thyroiditis (P = 0.05); the mean ADC val-
ues of the thyroid gland in Graves’ disease were 3.47, 
2.25 and 1.64×10–3 mm2/sec, and in Hashimoto thyroidi-
tis they were 2.53, 1.76, 1.28×10–3 mm2/sec for b-values 
of 100, 600, and 1000 sec/mm2, respectively. The ADC val-
ues obtained in patients with Graves’ disease were higher 
than those observed in patients with Hashimoto’s thyroidi-
tis [26]. Another study reported that the ADC values found 
in patients with Graves’ disease were significantly higher 
than those observed in patients with subacute thyroiditis 
and Hashimoto’s thyroiditis (sensitivity and specificity of 
75% and 80%, respectively) [24].
In this study, the ADC values that were observed in 
patients with Graves’ disease were significantly higher in 
comparison to those found in patients with painless thy-
roiditis. This is attributed to different pathological changes 
in both diseases. Graves’ disease is characterized by diffuse 
hyperplasia and hypertrophy of follicular cells, preserva-
tion of lobular architecture, prominent vascular congestion 
with tall follicular cells, and papillae that are associated 
with unrestricted diffusion and higher ADC values. In con-
trast, painless thyroiditis is caused by disrupted thyroid 
follicles which results in a release of preformed thyroid 
hormones. This process is associated with a diffuse lym-
phocytic infiltration in the thyroid gland. Hypercellularity 
in painless thyroiditis leads to numerous structural compo-
nents and membranes, resulting in greater impedance and 
restriction of diffusion of water molecules, which leads to 
lower ADC values [24,26,27].
In this study, the mean Tc-99m uptake values in Graves’ 
disease were significantly different (P=0.001) from those 
observed in painless thyroiditis. There was a positive cor-
relation between the ADC values of the thyroid gland and 
Tc-99m uptake values in all patients (r=0.74, P=0.001). 
Previous studies reported that thyroid scintigraphy is of a 
high diagnostic value for differentiating between Graves’ 
disease and painless thyroiditis, and it has been demon-
strated to be reliable [11–14]. Thyroid scintigraphy can 
indicate an enhanced isotope uptake in Graves’ disease 
as well as disruption of thyroid follicles and suppressed 
uptake in painless thyroiditis.
In the present study, the serum levels of TRAb were signifi-
cantly higher in Graves’ disease than in painless thyroidi-
tis, and both groups showed a positive correlation with the 
obtained ADC values (r=0.57, P=0.001). The TRAb titer 
has been demonstrated to be a useful serum marker that 
can be used to differentiate Graves’ disease from painless 
thyroiditis, although false positives and false negatives can 
occur; 5-10% of patients with Graves’ disease are negative 
for TRAb, and some patients with painless thyroiditis have 
positive TRAb titers [2,3,15–19].
One study reported that the optimal threshold of TRAb that 
was used to differentiate Graves’ disease from painless thy-
roiditis was 1.350 IU/ml, with sensitivity, specificity, accu-
racy, PPV, and NPV of 88.235%, 75.676%, 84.892%, 90.909%, 
and 70.000% respectively [27].
In this study, there was a positive correlation between ADC 
values and serum TSH levels, and a negative correlation 
with serum FT3 and FT4 in patients with thyrotoxicosis. A 
previous study reported that the ADC value of the thyroid 
gland in patients with Graves’ disease had a positive cor-
relation with TSH (r=0.87, P=0.001), and a negative cor-
relation with serum T4 (r=–0.82, P=0.001) and serum T3 
(r=–0.71, P=0.001) [25]. On the other hand, another study 
reported that the relationship between the ADC values of 
the thyroid gland, serum free T3, and serum free T4 levels 
was not significant in patients with diffuse thyroid disease 
[24]. The difference between that study and our study can 
be attributed to different b values and inclusion of patients 
with toxic nodular goiter and not with diffuse thyroid dis-
ease in [24].
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There are a few limitations of this study. First, this study 
was conducted in a small group of patients, with the use 
of a 1.5-tesla scanner. The application of a 3-tesla scan-
ner could improve the results. Second, as image analysis 
depends upon ROI selection, application of advanced image 
processing tools, such as histogram analysis, could increase 
the diagnostic performance of this technique. Third, this 
study applied diffusion-weighted MR imaging for assessing 
thyrotoxicosis. It is recommended that further studies use 
multi-parametric imaging with diffusion tensor MR imag-
ing, perfusion weighted MR imaging, and MR spectrosco-
py, which also could improve the results [28–32]. Fourth, 
there is no standard method for measuring ADC values and 
different methods of measuring ADC were not compared. 
Further evaluations that address these limitations are 
necessary.
Conclusions
We concluded that ADC values of the thyroid gland could 
be used to differentiate Graves’ disease from painless thy-
roiditis in patients with untreated thyrotoxicosis.
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